What is Supernus Pharmaceuticals's accrued product returns?

Supernus Pharmaceuticals (SUPN) reported accrued product returns of $37.23M in Q1 2026.

How has Supernus Pharmaceuticals's accrued product returns changed year-over-year?

Supernus Pharmaceuticals's accrued product returns decreased by 25.4% year-over-year, from $49.93M to $37.23M.

What is the long-term trend for Supernus Pharmaceuticals's accrued product returns?

Over 5 years (2020 to 2025), Supernus Pharmaceuticals's accrued product returns has grown at a 5.0% compound annual growth rate (CAGR), from $29.6M to $37.8M.

Supernus Pharmaceuticals SUPN Accrued product returns

Other financials

Income statement

See full

Revenue$207.7M+38.6%

Gross profit$184.3M+37.5%

Operating income-$8.3M+18.8%

Net income-$2.3M+80.6%

EPS (diluted)-$0.04+81.0%

Balance sheet

See full

Cash & equivalents$186.3M+60.8%

Total debt$40.9M+26.6%

Total equity$1.1B+4.5%

Total assets$1.5B+11.4%

Cash flow

See full

Operating cash flow$66.5M+117%

CapEx--100%

Free cash flow$66.5M+120%

Valuation

See full

Market cap$2.58B+62.8%

Enterprise value$2.44B+62.3%

P/S3.3×+0.9×

Profitability

See full

Gross margin89.4%+1.0pp

Operating margin-7.8%-18.9pp

Net margin-3.7%-13.0pp

FCF margin27.9%+3.4pp

Returns & leverage

See full

Return on equity-2.8%-9.1pp

Debt / equity0×0.0×

Current ratio2×-0.5×

Where this comes from

Reported directly by Supernus Pharmaceuticals in its filing.

Tagged under the XBRL concept supn:AccruedProductReturns.

The official record: Supernus Pharmaceuticals’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →

Ask your AI about Supernus Pharmaceuticals's accrued product returns.

Connect your AI assistant and see it in context, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Supernus Pharmaceuticals's accrued product returns?: Supernus Pharmaceuticals (SUPN) reported accrued product returns of $37.23M in Q1 2026.
How has Supernus Pharmaceuticals's accrued product returns changed year-over-year?: Supernus Pharmaceuticals's accrued product returns decreased by 25.4% year-over-year, from $49.93M to $37.23M.
What is the long-term trend for Supernus Pharmaceuticals's accrued product returns?: Over 5 years (2020 to 2025), Supernus Pharmaceuticals's accrued product returns has grown at a 5.0% compound annual growth rate (CAGR), from $29.6M to $37.8M.